最近有多种新药用于治疗尿路感染。较有意义的是一种口服剂型的羧苄青霉素——茚满基羧苄青霉素(indanyl carbenicillin)。此药对尿路感染有效,但对全身感染无效。此药最适宜于治疗假单胞菌属和耐其他药物的肠道菌尿路感染。然而,假单胞菌属或耐多种抗菌素的肠道菌感染患者往往还伴有解剖异常。现已充分认识,虽然一种药物在治疗期间可暂时奏效,但一旦停用抗菌素,并发感染迅速复发。因此,口服羧苄青霉素的指征似应限于异物已摘除或已用手术纠正异常,且系对此药特别敏感的细菌感染患者。对患者广泛应用口服剂型的羧苄青霉素不仅代价昂贵,且 There are several new drugs recently used to treat urinary tract infections. Of more interest is an oral dosage form of carbenicillin - indanyl carbenicillin. This medicine is effective for urinary tract infections but not for systemic infections. This medicine is most suitable for the treatment of enterobacteria urinary tract infections of Pseudomonas and other drugs. However, patients with Pseudomonas or enteric infections resistant to multiple antibiotics are often associated with anatomical abnormalities. It is well understood that although a drug may work temporarily during treatment, once the antibiotic is discontinued, the concurrent infection rapidly relaps. Therefore, the indication for oral carbenicillin should be limited to patients with bacterial infections that have been removed or that have been surgically corrected for anomalies and are particularly sensitive to the drug. The widespread use of oral carbenicillin for patients is not only costly, but also